" "


Would you like to receive stakeholder email notices about changes to the Preferred Drug Lists?

Request updates

Quarterly Washington Preferred Drug Lists


Quarter One | Quarter Two | Quarter Three

Drug class updates

Below are the Therapeutic Interchange Program announcements and updates to drug classes covered under the Washington Preferred Drug List.

Drug status on the PDL

Defining a drug’s “preferred” or “non-preferred” status on the PDL:

  • A “preferred” drug on the PDL is not subject to the Therapeutic Interchange Program (TIP).
  • A “non-preferred” drug on the PDL is subject to TIP when it is included in a Drug Effectiveness Review Project (DERP) report.
  • If a drug is part of a PDL drug class, but it has not been reviewed by DERP, it is considered "non-preferred". It is not subject to TIP or dispense as written, and will be covered according to each program's benefit design.

Selection process of preferred drugs on the PDL


For archived announcements on a drug class
Leta Evaskus
Phone: 206-521-2029